Accuracy of the API Campy system, the Vitek 2 Neisseria–Haemophilus card and matrix-assisted laser desorption ionization time-of-flight mass spectrometry for the identification of Campylobacter and related organisms  by Martiny, D. et al.
Accuracy of the API Campy system, the Vitek 2 Neisseria–Haemophilus
card and matrix-assisted laser desorption ionization time-of-ﬂight mass
spectrometry for the identiﬁcation of Campylobacter and related
organisms
D. Martiny1,2,*, A. Dediste1,2,*, L. Debruyne3, L. Vlaes1,2, N. B. Haddou1, P. Vandamme3 and O. Vandenberg1,2
1) National Reference Centre for Enteric Campylobacter, Saint Pierre University Hospital, 2) Department of Microbiology, Saint-Pierre University Hospital
and Jules Bordet Institute, Brussels and 3) Department of Biochemistry, Physiology and Microbiology, Faculty of Sciences, Ghent University, Ghent, Belgium
Abstract
Biochemical identiﬁcation of Campylobacter and related organisms is not always speciﬁc, and may lead to diagnostic errors. The API
Campy, the Vitek 2 system and matrix-assisted desorption ionization time-of-ﬂight mass spectrometry (MALDI-TOF MS) are commer-
cially available methods that are routinely used for the identiﬁcation of these microorganisms. In the present study, we used 224 clinical
isolates and ten reference strains previously identiﬁed by multiple PCR assays, whole cell protein proﬁling and either DNA–DNA hybrid-
ization or sequencing analysis to compare the reliability of these three methods for the identiﬁcation of Campylobacter and related patho-
gens. The API Campy accurately identiﬁed 94.4% of Campylobacter jejuni ssp. jejuni and 73.8% of Campylobacter coli, but failed to correctly
identify 52.3% of other Epsilobacteria. The Vitek 2 Neisseria–Haemophilus card correctly identiﬁed most C. jejuni ssp. jejuni (89.6%) and
C. coli (87.7%) strains, which account for the majority of campylobacterioses reported in humans, but it failed in the identiﬁcation of all
of the other species. Despite a good identiﬁcation rate for both C. jejuni ssp. jejuni and C. coli, both methods showed poor sensitivity in
the identiﬁcation of related organisms, and additional tests were frequently needed. In contrast to API Campy and Vitek, MALDI-
TOF MS correctly identiﬁed 100% of C. coli and C. jejuni strains tested. With an overall sensitivity of 98.3% and a short response time,
this technology appears to be a reliable and promising method for the routine identiﬁcation of Campylobacter and other Epsilobacteria.
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Introduction
Bacterial species within the class Epsilobacteria, especially
Campylobacter jejuni and Campylobacter coli, are the most
frequently reported bacterial causes of foodborne illness
worldwide. Recent reports suggest that Campylobacter infec-
tions may be followed by bacteraemia or septicaemia at an
estimated rate of 1.5 cases per 1000 intestinal infections.
Moreover, 0.1% of Campylobacter infections, especially C. jejuni
infections, are associated with the development of Guillain–
Barre´ syndrome [1].
With recent advances in diagnostic methods, the impor-
tance of at least 50 other species as possible causes of
gastroenteritis is now recognized [2]. In a previous study, we
showed a prevalence of non-jejuni/coli Campylobacter of 0.53%
in 67 599 stool specimens from 40 995 patients presenting
with abdominal complaints [3]. Non-jejuni/coli Campylobacter
strains also seem to be common in developing nations; in
South Africa, Lastovica et al. [4] found them in 12.0%
of 19 535 stool samples from children with diarrhoea. To
date, at least seven species, Campylobacter upsaliensis, C. jejuni
ssp. doylei, Campylobacter fetus ssp. fetus, Campylobacter conci-
sus, Arcobacter butzleri, Helicobacter fennelliae and Helicobacter
cinaedi, have been identiﬁed as emerging human gastrointesti-
nal pathogens [3,5–7].
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In most laboratories, the conventional identiﬁcation scheme
for Campylobacter and related microorganisms usually consists
of a few discriminatory tests, including growth temperature,
oxidase and catalase activities, cephalothin and nalidixic acid
susceptibility and hippurate hydrolysis. However, such simple
schemes may lead to identiﬁcation errors [8], and, in many
laboratories, the identiﬁcation of Campylobacter species is only
performed up to the genus level. However, correct identiﬁca-
tion is mandatory to provide information about the prevalence
and antimicrobial susceptibility patterns of the different
species, as well as to study speciﬁc risk factors.
Alternative identiﬁcation methods, such as a wide range of
PCR assays using either species-speciﬁc or multiplex reactions
and microarray-based identiﬁcation tests, have been devel-
oped [9]. However, most clinical laboratories do not use
these methods, but instead use manual or automatic commer-
cial identiﬁcation systems for Campylobacter identiﬁcation. For
about three decades, API Campy (BioMe´rieux, Marcy I’Etoile,
France), a miniaturized identiﬁcation system that includes 11
enzymatic and conventional tests and nine assimilation and
inhibition tests, has often been used for the routine identiﬁca-
tion of Campylobacter [10,11]. More recently, BioMe´rieux has
commercialized a Neisseria–Haemophilus (NH) identiﬁcation
card, which allows the identiﬁcation of C. jejuni, C. coli and
C. fetus with the Vitek 2 system [12,13]. In 2005, Mandrell
et al. described matrix-assisted laser desorption ionization
time-of-ﬂight mass spectrometry (MALDI-TOF MS) as a
promising identiﬁcation method for Campylobacter species
relevant to public health and food safety. This system could
therefore be used for the routine identiﬁcation of Campylo-
bacter and emerging Epsilobacteria [14–16].
However, to our knowledge, neither the NH card nor
MALDI-TOF MS has ever been extensively tested against
molecular methods for the routine identiﬁcation of Campylo-
bacter and other Epsilobacteria.
From a routine laboratory perspective, we have evaluated
the ability of these three commercial methods to identify a
random selection of strains obtained during an 8-year sur-
veillance survey. These strains were previously identiﬁed in
the course of a comparative study of several PCR-based
assays and/or sequencing analysis [9].
Materials and Methods
Bacterial cultures
The clinical isolates were obtained during an 8-year surveil-
lance study. During that period, stool samples submitted to
two Belgian hospital laboratories were routinely examined
macroscopically and microscopically, and cultured for common
bacterial pathogens. A total of 1906 Campylobacter-like organ-
isms were isolated, and biochemical identiﬁcation classiﬁed
1471 isolates as C. jejuni ssp. jejuni and 218 isolates as C. coli [9].
From these isolates, 224 strains that cover a wide range of
gastrointestinal pathogens (123 C. jejuni ssp. jejuni, 62 C. coli,
eight C. upsaliensis, six Campylobacter curvus, ﬁve C. fetus, ﬁve
Campylobacter lari, ﬁve C. jejuni ssp. doylei, three A. butzleri,
three Campylobacter hyointestinalis, two Arcobacter cryaerophilus,
one Campylobacter peloridis and one Helicobacter pullorum) were
selected. The collection was further supplemented with ten
reference strains (three C. coli, three A. butzleri, two C. jejuni
and two C. fetus). Strain details are provided in Table S1.
Most of the clinical isolates (185/224) were previously
included in an evaluation of several PCR-based identiﬁcation
methods using whole cell protein proﬁling and DNA–DNA
hybridization experiments as reference identiﬁcation meth-
ods [3,9]. The identiﬁcation results of the latter polyphasic
study were therefore used as the reference identiﬁcation for
the present study. The other strains were identiﬁed by clas-
sical biochemical testing and molecular methods; for a few of
them, partial 16S rDNA sequencing was performed in order
to conﬁrm the identiﬁcation (for details, see the Supporting
Information).
Before identiﬁcation by the three commercial methods
was performed, frozen isolates ()70C) were subcultured
twice onto Mueller–Hinton agar containing 5% sheep blood
(Oxoid, Erembodegem, Belgium) for 24–72 h at 37C in a
micro-aerobic atmosphere.
Methods
API Campy. API Campy identiﬁcation was performed accord-
ing to the manufacturer’s instructions. The results were
interpreted with the computerized automatic API Campy
analytical proﬁle index software.
NH card. NH card identiﬁcation of the strains was per-
formed according to the manufacturer’s instructions, as pre-
viously described [12]. The results were interpreted on the
basis of the software provided.
MALDI-TOF MS. The procedure used to identify the strains
by MALDI-TOF MS was adapted from the ‘ethanol/formic
acid extraction’ and ‘direct transfer’ procedures validated by
the manufacturer (Bruker, Bremen, Germany). In order to
prevent degradation of the proteins and to store samples for
further investigations, ethanol pellets were prepared from
fresh colonies in exponential growth phase. After centrifuga-
tion and discarding of the ethanol supernatant, inactivated
biological material from the pellet was directly smeared onto
a MALDI steel target plate. The following steps of the analy-
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sis were performed on the Microﬂex LT (Bruker), according
to the manufacturer’s instructions. The results obtained
were interpreted with the software provided; spectra were
compared with the MALDI Biotyper database (Bruker).
Among the 3287 entries (1820 species) included in the data-
base at that time, 35 were entries for ten of the 11 species
analysed in the present study.
Additional testing
In cases of doubtful identiﬁcation, additional tests are
proposed by the manufacturers of the API Campy and Vitek
systems. Most were performed in our laboratory (for details,
see Supporting Information). The MALDI-TOF MS ﬁnal
report did not suggest any additional testing in order to
discriminate related species; deﬁnitive identiﬁcations were
provided immediately.
Comparison
According to the conﬁdence levels provided by the three
software programs and the previously determined identiﬁca-
tion, the results obtained from the three methods were
divided, after initial reading and complementary testing, into
the following categories: ‘correct identiﬁcation of genus and
species’, ‘misidentiﬁcation’ and ‘no identiﬁcation’.
Results
Table 1 shows the results obtained by the three methods.
API Campy allowed correct identiﬁcation of 92.8% and
94.4% of C. jejuni ssp. jejuni strains at the initial reading and
after complementary testing, respectively (n = 125). This
method showed lower sensitivity for the identiﬁcation of
TABLE 1. Classiﬁcation of the results obtained from the three evaluated methods
After initial reading After additional testing
Correct
to genus and
species level,
no. (%)
Misidentiﬁcation,
no. (%)
No
identiﬁcation,
no. (%)
Additional
test required,
no. (%)
Correct to
genus and
species level,
no. (%)
Total
misidentiﬁcation
(%)
No
identiﬁcation
(%)
API Campy
C. jejuni ssp. jejuni 116/125 (92.8) – 7/125 (5.6) 2/125 (1.6) 118/125 (94.4) – 7/125 (5.6)
C. coli 36/65 (55.4) 3/65 (4.6) 4/65 (6.2) 22/65 (33.8) 48/65 (73.8) 3/65 (4.6) 14/65 (21.5)
C. upsaliensis 3/8 (37.5) – – 5/8 (62.5) 8/8 (100) – –
C. fetus 2/7 (28.6) – 5/7 (71.4) – 2/7 (28.6) – 5/7 (71.4)
C. curvusa – 2/6 (33.3) 3/6 (50) 1/6 (16.7) – 3/6 (50) 3/6 (50)
C. lari 2/5 (40) – – 3/5 (60) 3/5 (60) – 2/5 (40)
A. butzleria – – – 6/6 (100) – 6/6 (100) –
C. jejuni ssp. doylei 5/5 (100) – – – 5/5 (100) – –
C. hyointestinalis 1/3 (33.3) – 2/3 (66.7) – 1/3 (33.3) – 2/3 (66.7)
A. cryaerophilus 2/2 (100) – – – 2/2 (100) – –
C. peloridisa – – – 1/1 (100) – 1/1 (100) –
H. pulloruma – – – 1/1 (100) – – 1/1 (100)
Total 167/234 (71.4) 5/234 (2.1) 21/234 (9.0) 41/234 (17.5) 187/234 (79.9) 13/234 (5.6) 34/234 (14.5)
NH card
C. jejuni ssp. jejuni 101/125 (80.8) 13/125 (10.4) – 11/125 (8.8) 112/125 (89.6) 13/125 (10.4) –
C. coli 47/65 (72.3) 5/65 (7.7) 2/65 (3.1) 11/65 (16.9) 57/65 (87.7) 5/65 (7.7) 3/65 (4.6)
C. upsaliensisa – 4/8 (50) 1/8 (12.5) 3/8 (37.5) – 7/8 (87.5) 1/8 (12.5)
C. fetus – 4/7 (57.1) 1/7 (14.3) 2/7 (28.6) – 6/7 (85.7) 1/7 (14.3)
C. curvusa – – – 6/6 (100) – – 6/6 (100)
C. laria – – 1/5 (20) 4/5 (80) – – 5/5 (100)
A. butzleria – 5/6 (83.3) 1/6 (16.7) – – 5/6 (83.3) 1/6 (16.7)
C. jejuni ssp. doyleia – 4/5 (80) 1/5 (20) – – 4/5 (80) 1/5 (20)
C. hyointestinalisa – 2/3 (66.7) – 1/3 (33.3) – 3/3 (100) –
A. cryaerophilusa – – – 2/2 (100) – 2/2 (100) –
C. peloridisa – 1/1 (100) – – – 1/1 (100) –
H. pulloruma – 1/1 (100) – – – 1/1 (100) –
Total 148/234 (63.2) 39/234 (16.7) 7/234 (3.0) 40/234 (17.1) 169/234 (72.2) 47/234 (20.1) 18/234 (7.7)
MALDI-TOF MS
C. jejuni ssp. jejuni 125/125 (100) – – –
C. coli 65/65 (100) – – –
C. jejuni ssp. doylei 5/5 (100) – – –
C. upsaliensis 8/8 (100) – – –
C. fetus 7/7 (100) – – –
C. curvus 5/6 (83.3) – 1/6 (16.7) –
C. lari 5/5 (100) – – –
A. butzleri 6/6 (100) – – –
C. hyointestinalis 3/3 (100) – – –
A. cryaerophilus – – 2/2 (100) –
C. peloridisa – – 1/1 (100) –
H. pullorum 1/1 (100) – – –
Total 230/234 (98.3) 4/234 (1.7)
MALDI-TOF MS, matrix-assisted desorption ionization time-of-ﬂight mass spectrometry.
aNot included in the database.
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C. coli: 55.4% of strains after the initial reading and 73.8% of
strains after additional testing (n = 65).
The identiﬁcation of other Epsilobacteria by API Campy
was much more variable. A sensitivity of 100% was found for
the identiﬁcation of A. cryaerophilus (n = 2) and C. jejuni ssp.
doylei (n = 5). Although additional investigations were needed
for correct identiﬁcation, this method also had a sensitivity
of 100% for the identiﬁcation of C. upsaliensis (n = 8). Sixty
per cent of C. lari (n = 5) strains were correctly identiﬁed,
but the other 40% remained unidentiﬁed, even after comple-
mentary testing. About one-third of the C. fetus strains
(n = 7) and C. hyointestinalis strains (n = 3) were correctly
identiﬁed, and no additional testing was suggested to identify
the remaining strains.
API Campy was unable to correctly identify the H. pullo-
rum strain tested (no identiﬁcation, n = 1). API Campy mis-
identiﬁed all tested strains of A. butzleri (n = 6) and
C. peloridis (n = 1). Half of the C. curvus (n = 6) strains
were misidentiﬁed, whereas the other half remained uniden-
tiﬁed. The total misidentiﬁcation rate for this method was
5.6%.
Identiﬁcation of the C. coli strains with the NH card
rose from 72.3% upon initial reading to 87.7% after further
testing. Correct identiﬁcation of C. jejuni ssp. jejuni was
80.8% at the initial reading and 89.6% after additional test-
ing. Most of the C. jejuni ssp. doylei (80%, n = 5), A. butzleri
(83.3%, n = 6), C. fetus (85.7%, n = 7), C. upsaliensis (87.5%,
n = 8), C. hyointestinalis (100%, n = 3) and A. cryaerophilus
(100%, n = 2) strains, as well as the single C. peloridis and
H. pullorum strains included in the study, were misidenti-
ﬁed. The NH card provided no identiﬁcation for 100% of
C. curvus (n = 6) and C. lari (n = 5) strains. Overall, the
total misidentiﬁcation rate of the NH card was 20.1%.
Both methods needed a long incubation time to provide
identiﬁcation.
MALDI-TOF MS correctly identiﬁed 98.3% of the Epsilo-
bacteria strains tested. Only four of 234 isolates were not
identiﬁed, including 16.7% of C. curvus (n = 6) and 100% of
A. cryaerophilus (n = 2) and C. peloridis (n = 1) strains. How-
ever, the last species is not yet included in the database.
A complete target plate (96 targets) was analysed in a few
minutes.
Discussion
The data presented here demonstrate that three commercial
methods were able to correctly identify most C. jejuni ssp.
jejuni and C. coli strains, which account for most diagnosed
human Epsilobacteria infections.
API Campy had signiﬁcantly better sensitivity than the NH
card in the initial identiﬁcation of C. jejuni ssp. jejuni isolates.
However, after additional testing, the difference was not
statistically signiﬁcant (94.4% vs. 89.6%). Moreover, with API
Campy, <2% of the C. jejuni ssp. jejuni strains needed
additional testing, <6% remained unidentiﬁed and none were
misidentiﬁed (vs. 10.4% with the NH card).
In contrast, the NH card was better at identifying C. coli
than API Campy. The latter was unable to identify more than
25% of the C. coli strains, even after additional testing. How-
ever, the misidentiﬁcation rate for C. coli with the NH card
was about 8%, and 4.6% of the strains remained unidentiﬁed
by this method.
A lower identiﬁcation rate of C. coli by API Campy was
previously reported by Huysmans et al. [10], who compared
this method with the conventional tests and concluded that
the system offered no advantages.
Regarding the performance of the NH card, these results
are in disagreement with those obtained by others [12,13],
who showed an overall better identiﬁcation rate for C. jejuni
(94%, n = 18 [12]; 100% after additional tests, n = 27 [13]).
For the identiﬁcation of C. coli, different authors have
obtained contradictory results, but the number of tested
strains was too small for a signiﬁcant comparison to be made
75%, n = 4 [12]; 100%, n = 9 [13]).
The performance of MALDI-TOF MS is signiﬁcantly better,
with an excellent sensitivity of 100%. Moreover, no addi-
tional testing was required to correctly identify C. jejuni ssp.
jejuni and C. coli with this technology, the preparation of sam-
ples was at least as easy as for the other methods, and the
results were obtained much more quickly (1 h instead of
24–48 h for the other methods).
The results obtained for the identiﬁcation of the other
species (n = 44), which represent more than 11% of all
Epsilobacteria isolated from stool specimens [3] and may also
be recovered from blood samples, show more variations
between the three methods.
API Campy allowed the correct identiﬁcation of all
A. cryaerophilus, C. jejuni ssp. doylei and C. upsaliensis strains.
However, to obtain these results, either a prolonged incuba-
tion time is needed, or additional tests must be performed,
both extending the time needed for identiﬁcation. C. curvus,
H. pullorum, C. peloridis and A. butzleri were not correctly
identiﬁed by this method, which is expected, as these species
are not included in the database. Unexpected poor sensitivity
levels were found for the identiﬁcation of C. lari, C. fetus and
C. hyointestinalis, even though these species are included in
the manufacturer’s identiﬁcation table. Finally, 22.7% of the
non-jejuni/coli Campylobacter strains were misidentiﬁed, and
29.5% remained unidentiﬁed.
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The NH card failed to identify any other Campylobacter
species, even though C. fetus is included in its database. As
expected, related genera such as Helicobacter and Arcobacter
could not be identiﬁed by this method. Finally, 65.9% of
these 44 strains were misidentiﬁed by the Vitek technology,
and this represents an important rate of diagnostic error.
The poor performances of API Campy and the NH card
can be explained by the low number of discriminatory tests
included in the devices. Indeed, 15 phenotypic characteristics
have to be taken into account to discriminate Campylobacter
and Arcobacter species [2]. Among the ten biochemical tests,
only four are included in API Campy (nitrate reduction,
hippurate hydrolysis, and urease and H2S production;
catalase production is included in the method, but must be
performed separately). Sensitivity to nalidixic acid is also
tested by API Campy, but cephalotin resistance has to be
evaluated by an additional test. Among the three growth
tests, only one, growth at 25C, is suggested by the API
system as part of the additional testing. The NH card
includes only one of the ten biochemical tests (urease). Only
a few useful additional tests are suggested by the system’s
manufacturer to discriminate Campylobacter and Arcobacter
species, including catalase production, hippurate hydrolysis
and growth at 25C.
In the case of suspicion of Campylobacter, we propose the
following rules to interpret identiﬁcation results obtained by
these methods. The identiﬁcation results categorized as
‘excellent identiﬁcation to species level’ or ‘very good identi-
ﬁcation to species level’ according to the instructions of the
manufacturer, without or after additional tests, should be
considered reliable. Other results are not reliable, and, in
these cases, molecular tests or MALDI-TOF MS should be
performed when accurate identiﬁcation is of concern.
Following this algorithm, the overall misidentiﬁcation rate in
the present study would have decreased from 5.6% to 0%
and from 20.1% to 2.5% for API Campy and the NH card,
respectively.
MALDI-TOF MS was shown to be superior to the other
two methods, rapidly allowing the correct identiﬁcation of
90.9% of the non-jejuni/coli Epsilobacteria strains. Moreover,
this method did not lead to any misidentiﬁcations. Our
observations concerning MALDI-TOF MS are in accordance
with previously reported data [15,16] from studies per-
formed on a limited number of reference strains, which also
highlight the reliability of this technology.
In conclusion, the identiﬁcation results for Campylobacter
and related organisms obtained with API Campy and the NH
card, which are widely used in clinical laboratories, must be
interpreted with caution. Although both methods give satis-
factory results for the identiﬁcation of C. coli and C. jejuni ssp.
jejuni, the overall misidentiﬁcation rate for related species
remains important.
Among the three evaluated commercial systems, MALDI-
TOF MS appears to be the method of choice for the identiﬁ-
cation of Campylobacter and related microorganisms.
In addition to its ability to identify a large range of
Epsilobacteria species with excellent sensitivity (98.3%) and
speciﬁcity (100%), this reliable technology is also faster than
all of the other available methods. Moreover, the analysis is
easy to perform and requires few biological and technical
materials.
The inability to provide information on bacterial resistance
is probably the main weakness of MALDI-TOF MS, followed
by the absence of a computerized expert system. Indeed, the
suggestion of additional tests to discriminate species is help-
ful for the microbiologist in routine practice.
In the future, an expansion of the database to include
larger numbers of infrequently encountered Campylobacter
species and other Epsilobacteria species, and additional stud-
ies on the direct use of the sample, will further improve the
usefulness of this technology for microbiologists [7].
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